Paper39304595
Prediction of First-in-Human Dose of Chimeric Antigen Receptor-T (CAR-T) Cells from Mice.
Mahmood I. Eur J Drug Metab Pharmacokinet, 2024. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Prediction of First-in-Human Dose of Chimeric Antigen Receptor-T (CAR-T) Cells from Mice. Papers, record 39304595. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39304595
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Prediction of First-in-Human Dose of Chimeric Antigen Receptor-T (CAR-T) Cells from Mice.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Receptors, Chimeric Antigen | Major topic |
| Immunotherapy, Adoptive | Major topic |
| Animals | |
| Mice | |
| Humans | |
| Body Weight | |
| T-Lymphocytes |
Source PubMed
References18
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33632155 | Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies. | BMC Cancer | 2021 | https://conductscience.org/library/papers/33632155 | PubMed |
| 2 | 9336307 | The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. | J Pharmacol Exp Ther | 1997 | https://conductscience.org/library/papers/9336307 | PubMed |
| 3 | 8378254 | Physiological parameters in laboratory animals and humans. | Pharm Res | 1993 | https://conductscience.org/library/papers/8378254 | PubMed |
| 4 | 32042751 | Preclinical safety evaluation of chimeric antigen receptor-modified T cells against CD19 in NSG mice. | Ann Transl Med | 2019 | https://conductscience.org/library/papers/32042751 | PubMed |
| 5 | 8568013 | First-time-in-human dose selection: allometric thoughts and perspectives. | J Clin Pharmacol | 1995 | https://conductscience.org/library/papers/8568013 | PubMed |
| 6 | 34562983 | A Single Animal Species-Based Prediction of Human Clearance and First-in-Human Dose of Monoclonal Antibodies: Beyond Monkey. | Antibodies (Basel) | 2021 | https://conductscience.org/library/papers/34562983 | PubMed |
| 7 | 19837907 | Interspecies scaling of therapeutic monoclonal antibodies: initial look. | J Clin Pharmacol | 2009 | https://conductscience.org/library/papers/19837907 | PubMed |
| 8 | 16172177 | How first-time-in-human studies are being performed: a survey of phase I dose-escalation trials in healthy volunteers published between 1995 and 2004. | J Clin Pharmacol | 2005 | https://conductscience.org/library/papers/16172177 | PubMed |
| 9 | 33430196 | Interspecies Scaling of Antibody-Drug Conjugates (ADC) for the Prediction of Human Clearance. | Antibodies (Basel) | 2021 | https://conductscience.org/library/papers/33430196 | PubMed |
| 10 | 19177515 | Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation. | J Pharm Sci | 2009 | https://conductscience.org/library/papers/19177515 | PubMed |
| 11 | 32755128 | Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients | Turk J Haematol | 2020 | https://conductscience.org/library/papers/32755128 | PubMed |
| 12 | 11936701 | Estimating the starting dose for entry into humans: principles and practice. | Eur J Clin Pharmacol | 2002 | https://conductscience.org/library/papers/11936701 | PubMed |
| 13 | 12861964 | Selection of the first-time dose in humans: comparison of different approaches based on interspecies scaling of clearance. | J Clin Pharmacol | 2003 | https://conductscience.org/library/papers/12861964 | PubMed |
| 14 | 33753909 | Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. | Gene Ther | 2021 | https://conductscience.org/library/papers/33753909 | PubMed |
| 15 | 6396053 | Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. | Drug Metab Rev | 1984 | https://conductscience.org/library/papers/6396053 | PubMed |
| 16 | 35848614 | Preliminary Report of the Academic CAR-T (ISIKOK-19) Cell Clinical Trial in Turkey: Characterization of Product and Outcomes of Clinical Application | Turk J Haematol | 2022 | https://conductscience.org/library/papers/35848614 | PubMed |
| 17 | 28039267 | Potent Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia. | Clin Cancer Res | 2017 | https://conductscience.org/library/papers/28039267 | PubMed |
| 18 | 25505964 | Clinical application of genetically modified T cells in cancer therapy. | Clin Transl Immunology | 2014 | https://conductscience.org/library/papers/25505964 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 41884842 | Smart control of CAR-T cells: emerging strategies for safer and more effective cancer immunotherapy. | Front Immunol | 2026 | https://conductscience.org/library/papers/41884842 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39304595
GET https://conductscience.org/api/papers/v1/39304595/authors